PCM
SONN

Perkins Capital Management’s Sonnet BioTherapeutics SONN Stock Holding History

Perkins Capital Management’s Portfolio SONN Stock Details SONN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed -$110K – 133
2018
Q3 		$110K Hold
1
– – 0.07% 121
2018
Q2 		$210K Buy
+1
New +$209K 0.15% 111

Other funds holding SONN

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
IC
Intersect Capital San Ramon, California $331M AUM 6.79% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perkins Capital Management's SONN Position: Q4 2018 in Review

Perkins Capital Management sold out of Sonnet BioTherapeutics (SONN) in Q4 2018, closing a stake of 1 share — an estimated $110K sold.

Perkins Capital Management first reported a position in SONN in Q2 2018 and held it in 2 quarters. The position peaked at $210K in Q2 2018. 0 funds tracked by Wall St. Rank hold SONN as of Q4 2018.

  • Perkins Capital Management reported no remaining Sonnet BioTherapeutics position as of Q4 2018 after selling out during the quarter.
  • Perkins Capital Management sold 1 Sonnet BioTherapeutics share in Q4 2018, an estimated $110K.
  • Perkins Capital Management first reported a position in Sonnet BioTherapeutics in Q2 2018 and held it in 2 quarters.
  • Perkins Capital Management's Sonnet BioTherapeutics position peaked at $210K in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2018.

Based on Perkins Capital Management's 13F filing for Q4 2018, filed 11 Feb 2019.